Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy

Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclin...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Madhav, Newberry, Kate J, Romaguera, Jorge, Zhang, Liang, Ou, Zhishuo, Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735404/
https://www.ncbi.nlm.nih.gov/pubmed/23915913
http://dx.doi.org/10.1186/1756-8722-6-55
_version_ 1782279639397302272
author Desai, Madhav
Newberry, Kate J
Romaguera, Jorge
Zhang, Liang
Ou, Zhishuo
Wang, Michael
author_facet Desai, Madhav
Newberry, Kate J
Romaguera, Jorge
Zhang, Liang
Ou, Zhishuo
Wang, Michael
author_sort Desai, Madhav
collection PubMed
description Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.
format Online
Article
Text
id pubmed-3735404
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37354042013-08-07 Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy Desai, Madhav Newberry, Kate J Romaguera, Jorge Zhang, Liang Ou, Zhishuo Wang, Michael J Hematol Oncol Review Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas. BioMed Central 2013-08-02 /pmc/articles/PMC3735404/ /pubmed/23915913 http://dx.doi.org/10.1186/1756-8722-6-55 Text en Copyright © 2013 Desai et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Desai, Madhav
Newberry, Kate J
Romaguera, Jorge
Zhang, Liang
Ou, Zhishuo
Wang, Michael
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
title Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
title_full Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
title_fullStr Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
title_full_unstemmed Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
title_short Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy
title_sort immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large b cell lymphoma: current data on safety and efficacy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735404/
https://www.ncbi.nlm.nih.gov/pubmed/23915913
http://dx.doi.org/10.1186/1756-8722-6-55
work_keys_str_mv AT desaimadhav immunomodulationtherapywithlenalidomideinfolliculartransformedanddiffuselargebcelllymphomacurrentdataonsafetyandefficacy
AT newberrykatej immunomodulationtherapywithlenalidomideinfolliculartransformedanddiffuselargebcelllymphomacurrentdataonsafetyandefficacy
AT romaguerajorge immunomodulationtherapywithlenalidomideinfolliculartransformedanddiffuselargebcelllymphomacurrentdataonsafetyandefficacy
AT zhangliang immunomodulationtherapywithlenalidomideinfolliculartransformedanddiffuselargebcelllymphomacurrentdataonsafetyandefficacy
AT ouzhishuo immunomodulationtherapywithlenalidomideinfolliculartransformedanddiffuselargebcelllymphomacurrentdataonsafetyandefficacy
AT wangmichael immunomodulationtherapywithlenalidomideinfolliculartransformedanddiffuselargebcelllymphomacurrentdataonsafetyandefficacy

Ejemplares similares